There was a significant reduction in plasma glucose levels in the MSDC-0160 100-mg group (least-squares mean difference of −18.4 mg/dl; P = 0.0057), the MSDC-0160 150-mg group (least-squares mean difference of −28.9 mg/dl; P < 0.0001), and the pioglitazone group (least-squares mean difference of −31 mg/dl; P < 0.0001).
MSDC-0160 (an mTOT modulator)
45 mg pioglitazone HCl (a PPAR-γ agonist)
high-molecular-weight (HMW) adiponectin